Equities
  • Price (EUR)496.00
  • Today's Change5.00 / 1.02%
  • Shares traded0.00
  • 1 Year change+51.94%
  • Beta--
Data delayed at least 15 minutes, as of Mar 27 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

McKesson Corporation is a provider of diversified healthcare services. The Company is engaged in advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over the counter (OTC) pharmaceutical drugs and other healthcare-related products in the United States. Its Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies. Its International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada.

  • Revenue in USD (TTM)301.51bn
  • Net income in USD3.00bn
  • Incorporated1994
  • Employees45.00k
  • Location
    Mckesson Corp6555 State Highway 161IRVING 75039United StatesUSA
  • Phone+1 (972) 446-4800
  • Fax+1 (302) 636-5454
  • Websitehttps://www.mckesson.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MCK:NYQ since
announced
Transaction
value
Compile IncDeal completed04 Jan 202404 Jan 2024Deal completed11.91%--
Data delayed at least 15 minutes, as of Mar 28 2024 14:22 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.